In the CAMELIA clinical trial, we demonstrated that the capacity for NK cell degranulation, as defined by CD107a expression by exocytosis, was higher in TB-IRIS individuals than in those without TB-IRIS before cART initiation [37]. The gene discussed is LAMP1; the disease is tuberculosis.